AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about AMGEN INC.
05/23WALL STREET STOCK EXCHANGE : Biden comments reassure investors
05/23SVB Securities Initiates Amgen at Market Perform With $256 Price Target
MT
05/23ANALYST RECOMMANDATIONS : AbbVie, Amgen, Caterpillar, HP, Nike...
05/16AMGEN INC. : Ex-dividend day for
FA
05/13Avantor Names Jonathan Peacock Chairman
MT
05/12Amgen and lance bass partner to encourage people to do a 'double take' to recognize the..
PR
05/12BridgeBio Inks BBP-398 License With Bristol Myers
DJ
05/11TRANSCRIPT : Amgen Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-202..
CI
05/11INSIDER SELL : Amgen
MT
05/10Pfizer to pay $11.6 bln for Biohaven to tap migraine market
RE
05/10Mizuho Securities Lifts Amgen's Price Target to $208 From $202, Citing Repatha Peak Rev..
MT
05/09Amgen announces webcast of 2022 bank of america healthcare conference
AQ
05/06Amgen announces webcast of 2022 bank of america healthcare conference
PR
05/04Will The Supreme Court Take The Bait? CVSG Issued And Other Updates In The Amgen v. San..
AQ
05/04BeiGene Says China Gives Conditional Approval to Blincyto Injection for Pediatric Acute..
MT
05/02Amgen releases annual environmental, social & governance report
PR
04/28Wall Street ends sharply higher, lifted by Meta and Apple
RE
04/28Goldman Sachs Adjusts Price Target for Amgen to $291 From $287, Maintains Buy Rating
MT
04/28BMO Capital Adjusts Amgen's Price Target to $243 from $263, Keeps Market Perform Rating
MT
04/28UBS Adjusts Amgen Price Target to $245 From $251, Maintains Neutral Rating
MT
04/28RBC Lifts Price Target on Amgen to $223 From $218, Maintains Sector Perform Rating
MT
04/28Piper Sandler Adjusts Amgen's Price Target to $260 From $255, Reiterates Overweight Rat..
MT
04/28Molecular Partners to Regain Global Rights To MP0310
MT
04/27AMGEN : REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS - Form 8-K
PU
04/27US Stocks Inch Higher With Nasdaq Closing Flat Ahead of Meta, Qualcomm Results
MT
04/27TRANSCRIPT : Amgen Inc., Q1 2022 Earnings Call, Apr 27, 2022
CI
04/27Amgen says IRS seeks billions in back taxes, shares fall 6%
RE
04/27US Stocks Close Higher on Wednesday, With Nasdaq Ending Marginally Lower Ahead of Quart..
MT
04/27AMGEN : Q1 Earnings Snapshot
AQ
04/27Amgen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/27Tranche Update on Amgen Inc.'s Equity Buyback Plan announced on April 21, 2011.
CI
04/27Amgen Inc. Provides Earnings Guidance for the Year 2022
CI
04/27Amgen Q1 Non-GAAP EPS, Revenue Higher; Releases 2022 Guidance
MT
04/27Big Biotech Firms Have Several Catalysts Lined Up, UBS Says
MT
04/27Earnings Flash (AMGN) AMGEN Reports Q1 Revenue $6.24B, vs. Street Est of $6.115B
MT
04/27Earnings Flash (AMGN) AMGEN Posts Q1 EPS $4.25, vs. Street Est of $4.13
MT
04/27Amgen 1Q Revenue Beats Expectations, Profit Declines
DJ
04/27EARNINGS REACTION HISTORY : Amgen Inc, 70.0% Follow-Through Indicator, 3.7% Sensitive
MT
04/27UBS Adjusts Amgen Price Target to $251 From $235, Maintains Neutral Rating
MT
04/27Amgen Says Two Studies of Repatha Show Decrease in Cholesterol Levels
MT
04/27Wall Street Set to Open Higher; Nasdaq Lags After Lackluster Alphabet Earnings
MT
04/27Amgen announces results from two open label extension studies of repatha® (evolocumab)
PR
04/27Amgen Announces Top-Line Results from Two Repatha® Open Label Extension Studies to the ..
CI
04/27Top Premarket Decliners
MT
04/26Molecular Partners Gets Back Global Rights of Solid Tumor Therapy From Amgen; Shares Do..
MT
04/26Amgen Q1 Results May Reflect COVID-19 Pandemic Recovery, Longer-Term Outlook, Oppenheim..
MT
04/22AMGEN : One Woman's Inspiring Journey from Cleaning Labs to Cleaning the Planet
PU
04/22Amgen announces webcast of 2022 first quarter financial results
PR
04/20AMGEN : Improving Diversity in Our Clinical Trials for Long-term Health Equity
PU
04/20Federal Circuit Reverses PTAB Decision In Amgen Biosimilar-Related IPR Appeal
AQ
04/18Amgen Meets Primary Efficacy Endpoint in Comparative Study of Biosimilar Candidate to S..
MT
04/18Amgen announces positive top-line results from phase 3 study of abp 654, biosimilar can..
PR
04/18Amgen Announces Positive Top-Line Results from Phase 3 Study of ABP 654 Compared to STE..
CI
04/13Abbvie Vice Chairman Severino Departs for Flagship Pioneering
DJ
04/12AMGEN : Manufacturing Site in Puerto Rico Celebrates 30 Years of Producing Medicines Reach..
PU
04/12Morgan Stanley Adjusts Amgen's Price Target to $237 from $238, Keeps Equalweight Rating
MT
04/12Barclays Adjusts Price Target for Amgen to $236 From $233, Maintains Equalweight Rating
MT
04/11Amgen Says Follow-Up Data on Lumakras Show Long-Term Benefit in Lung Cancer
MT
04/10Amgen Inc. Announces the Presentation of Long-Term Efficacy and Safety Data from the Co..
CI
04/07AMGEN : 5 Things Amgen is Doing to Help Bend the Curve in Cardiovascular Disease
PU
04/07FIGHTING THE FIGHT : Breaking Down Barriers to Equal Cancer Care
PU
04/04Pharma industry-backed fund invests in two biotech companies to treat 'superbugs'
RE
03/29AMGEN : CEO Bob Bradway's 2021 Letter To Shareholders
PU
03/29AMGEN : Chairman and CEO Letter and Amgen Inc. 2021 Annual Report
PU
03/28GATC Health Gets Stronger, Adds More Firepower To An Already Stellar Management Team Ad..
AQ
03/25Amgen Says New Data on Otezla 'Reinforces' Benefit for Plaque Psoriasis, Palmoplantar P..
MT
03/24AMGEN : Three Amgen Leaders Recognized for Advancing Gender Equity
PU
03/24Parties In Amgen v. Hospira Pegfilgrastim Litigation Stipulate To Dismissal Of All Clai..
AQ
03/17AMGEN : Initial Statement of Beneficial Ownership (Form 3)
PU
03/17PGR Challenge To Genus Claims Fails Because Of Enabling Disclosure Of Species In Pre-AI..
AQ
03/16TRANSCRIPT : Amgen Inc. Presents at Oppenheimer's 32nd Annual Healthcare Conference, Mar-1..
CI
03/14U.S. FDA declines to approve AstraZeneca treatment for chronic nasal condition
RE
03/10Amgen To Present At The 32nd annual Oppenheimer Healthcare Conference
PR
03/09Amgen to present long-term outcomes for lumakras (sotorasib) in kras g12c-mutated nsclc..
AQ
03/08AMGEN : Breaks Ground on New Drug Substance Manufacturing Facility in North Carolina
PU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on AMGEN INC.